胰腺腺鳞癌临床治疗的探讨
Exploration of the Clinical Treatment of Adenosquamous Carcinoma of the Pancreas
DOI: 10.12677/acm.2025.1551603, PDF,   
作者: 王一涵, 刘冰冰, 刘红山*, 岳学良, 杨 森:郑州大学人民医院肝胆胰腺外科一病区,河南 郑州
关键词: 胰腺腺鳞癌临床治疗Pancreatic Adenosquamous Carcinoma Clinical Treatment
摘要: 目的:对胰腺腺鳞癌的临床治疗进行初步探讨,以期提高临床认识和诊治水平,改善预后。方法:回顾性分析胰腺腺鳞癌的临床治疗8例,并结合文献资料进行讨论。结果:8例患者均经手术治疗,围手术期无死亡病例,术后3例联合化疗,平均生存期(7.4 ± 1.2)个月,中位生存期(7.3 ± 1.7)个月。结论:胰腺腺鳞癌恶性度高,预后差,R0手术切除是目前最有效的治疗方法,但联合脏器切除需注意损伤控制,术后联合放化疗等辅助治疗有助于生存期延长,但仍需临床进一步研究完善。从肿瘤学的角度出发开展多学科协作诊疗有可能成为提高胰腺腺鳞癌治疗效果的有效手段之一,免疫治疗也有可能为胰腺腺鳞癌的临床治疗带来新的思路。
Abstract: Objective: To study the clinical treatment of pancreatic adenosquamous carcinoma, in order to improve clinical recognition, diagnosis and treatment, and improve the prognosis. Methods: 8 cases of pancreatic adenosquamous carcinoma were analyzed retrospectively and discussed with the literature. Results: All of the 8 patients were treated by operation. There was no death in the perioperative period. The mean survival time was (7.4 ± 1.2) months and the median survival time was (7.3 ± 1.7) months. Conclusion: The malignant degree of pancreatic adenosquamous carcinoma is high and the prognosis is poor. R0 resection is the most effective treatment at present, but the combined organ resection needs to pay attention to damage control, postoperative adjuvant therapy such as radiotherapy and chemotherapy can help to prolong the survival period, but it still needs further clinical research and improvement. From the perspective of oncology, multi-disciplinary team may become one of the effective means to improve the therapeutic effect of pancreatic adenosquamous carcinoma. Immunotherapy may also bring new ideas for the clinical treatment of pancreatic adenosquamous carcinoma.
文章引用:王一涵, 刘冰冰, 刘红山, 岳学良, 杨森. 胰腺腺鳞癌临床治疗的探讨[J]. 临床医学进展, 2025, 15(5): 2149-2156. https://doi.org/10.12677/acm.2025.1551603

参考文献

[1] Ito, T., Sugiura, T., Okamura, Y., Yamamoto, Y., Ashida, R., Ohgi, K., et al. (2019) Long-Term Outcomes after an Aggressive Resection of Adenosquamous Carcinoma of the Pancreas. Surgery Today, 49, 809-819. [Google Scholar] [CrossRef] [PubMed]
[2] Katz, M.H.G., Taylor, T.H., Al-Refaie, W.B., Hanna, M.H., Imagawa, D.K., Anton-Culver, H., et al. (2011) Adenosquamous versus Adenocarcinoma of the Pancreas: A Population-Based Outcomes Analysis. Journal of Gastrointestinal Surgery, 15, 165-174. [Google Scholar] [CrossRef] [PubMed]
[3] Hester, C.A., Augustine, M.M., Choti, M.A., Mansour, J.C., Minter, R.M., Polanco, P.M., et al. (2018) Comparative Outcomes of Adenosquamous Carcinoma of the Pancreas: An Analysis of the National Cancer Database. Journal of Surgical Oncology, 118, 21-30. [Google Scholar] [CrossRef] [PubMed]
[4] Komatsu, H., Egawa, S., Motoi, F., Morikawa, T., Sakata, N., Naitoh, T., et al. (2014) Clinicopathological Features and Surgical Outcomes of Adenosquamous Carcinoma of the Pancreas: A Retrospective Analysis of Patients with Resectable Stage Tumors. Surgery Today, 45, 297-304. [Google Scholar] [CrossRef] [PubMed]
[5] Voong, K.R., Davison, J., Pawlik, T.M., Uy, M.O., Hsu, C.C., Winter, J., et al. (2010) Resected Pancreatic Adenosquamous Carcinoma: Clinicopathologic Review and Evaluation of Adjuvant Chemotherapy and Radiation in 38 Patients. Human Pathology, 41, 113-122. [Google Scholar] [CrossRef] [PubMed]
[6] Hoshimoto, S., Hoshi, N., Hishinuma, S., Shirakawa, H., Tomikawa, M., Ozawa, I., et al. (2017) Clinical Implications of the Proliferative Ability of the Squamous Component Regarding Tumor Progression of Adenosquamous Carcinoma of the Pancreas: A Preliminary Report. Pancreatology, 17, 788-794. [Google Scholar] [CrossRef] [PubMed]
[7] Taniwaki, S., Hisaka, T., Sakai, H., Goto, Y., Nomura, Y., Kawahara, R., et al. (2019) Sarcomatous Component in Pancreatic Adenosquamous Carcinoma: A Clinicopathological Series of 7 Cases. Anticancer Research, 39, 4575-4580. [Google Scholar] [CrossRef] [PubMed]
[8] Del Arco, H., Chakiba-Brugère, C., Salabert, L. and Béchade, D. (2019) Adenosquamous Carcinoma of the Pancreas. Clinical Medicine Insights: Oncology, 13. [Google Scholar] [CrossRef] [PubMed]
[9] Boyd, C.A., Benarroch-Gampel, J., Sheffield, K.M., Cooksley, C.D. and Riall, T.S. (2012) 415 Patients with Adenosquamous Carcinoma of the Pancreas: A Population-Based Analysis of Prognosis and Survival. Journal of Surgical Research, 174, 12-19. [Google Scholar] [CrossRef] [PubMed]
[10] Smoot, R.L., Zhang, L., Sebo, T.J. and Que, F.G. (2008) Adenosquamous Carcinoma of the Pancreas: A Single-Institution Experience Comparing Resection and Palliative Care. Journal of the American College of Surgeons, 207, 368-370. [Google Scholar] [CrossRef] [PubMed]
[11] Boecker, J., Feyerabend, B., Tiemann, K., Buchwalow, I., Wagner, K.C., Oldhafer, K.J., et al. (2020) Adenosquamous Carcinoma of the Pancreas Comprise a Heterogeneous Group of Tumors with the Worst Outcome: A Clinicopathological Analysis of 25 Cases Identified in 562 Pancreatic Carcinomas Resected with Curative Intent. Pancreas, 49, 683-691. [Google Scholar] [CrossRef] [PubMed]
[12] Regi, P., Butturini, G., Malleo, G., Pedica, F., D’Onofrio, M. and Bassi, C. (2010) Clinicopathological Features of Adenosquamous Pancreatic Cancer. Langenbecks Archives of Surgery, 396, 217-222. [Google Scholar] [CrossRef] [PubMed]
[13] Wild, A.T., Dholakia, A.S., Fan, K.Y., et al. (2015) Efficacy of Platinum Chemotherapy Agents in the Adjuvant Setting for Adenosquamous Carcinoma of the Pancreas. Journal of Gastrointestinal Oncology, 6, 115-125.
[14] Fang, Y., Pu, N., Zhang, L., Wu, W. and Lou, W. (2019) Chemoradiotherapy Is Associated with Improved Survival for Resected Pancreatic Adenosquamous Carcinoma: A Retrospective Cohort Study from the SEER Database. Annals of Translational Medicine, 7, Article 522. [Google Scholar] [CrossRef] [PubMed]
[15] Komatsu, H., Kashiwazaki, M., Hasegawa, N., et al. (2019) A Case of Adenosquamous Carcinoma of Pancreas Treated with Conversion Surgery after Systemic Chemotherapy. Gan To Kagaku Ryoho, 46, 546-548.
[16] Simone, C.G., Toro, T.Z., Chan, E., et al. (2019) Characteristics and Outcomes of Adenosquamous Carcinoma of the Pancreas. Pancreas, 48, 817-822.
[17] Kudo, H., Seyama, Y., Kanomata, H., et al. (2019) A Case of Resection of Advanced Pancreatic Adenosquamous Carcinoma in which Multidisciplinary Treatment Was Effective. Gan To Kagaku Ryoho, 46, 178-180.
[18] Tanigawa, M., Naito, Y., Akiba, J., Kawahara, A., Okabe, Y., Ishida, Y., et al. (2018) PD-L1 Expression in Pancreatic Adenosquamous Carcinoma: PD-L1 Expression Is Limited to the Squamous Component. PathologyResearch and Practice, 214, 2069-2074. [Google Scholar] [CrossRef] [PubMed]
[19] Silvestris, N., Brunetti, O., Pinto, R., Petriella, D., Argentiero, A., Fucci, L., et al. (2018) Immunological Mutational Signature in Adenosquamous Cancer of Pancreas: An Exploratory Study of Potentially Therapeutic Targets. Expert Opinion on Therapeutic Targets, 22, 453-461. [Google Scholar] [CrossRef] [PubMed]
[20] Lee, S.M. and Sung, C.O. (2021) PD-L1 Expression and Surgical Outcomes of Adenosquamous Carcinoma of the Pancreas in a Single-Centre Study of 56 Lesions. Pancreatology, 21, 920-927. [Google Scholar] [CrossRef] [PubMed]